Case todayStrengtheningInsider buying clusterThe case · mixed · Nov 21, 2026Own VANI if Vivani is a binary platform bet: NanoPortal implants must prove they can make chronic-drug delivery easier and more consistent before cash burn and dilution overwhelm the option value.5 conditions2 holding · 3 weakeningNext resultsFeb 11, 2027Projected from its filing dates

VANI at a glance

The past year

Chart

−16.8% $1.14, close Nov 20

From the highest close
−28.8%
Vs the 200-day average
−7.5%
Nov 19, 2025Daily close, Vivani MedicalNov 20, 2026

Short interest

History

369,789 shares

Of shares outstanding
0.41%
Since the last report
−11.4%
Days to cover
2.0 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

2 insiders bought

Purchases
1
On this week's list
Yes
Form 4s filed
Nov 16 – Nov 22

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

VANI price history

Latest price$1.14Today+$0.05 (+4.59%)
VANI -0.87%S&P 500 -10.82%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • NanoPortal must create a real patient and prescriber advantage—reversible, ultra-long-acting, near constant-rate delivery—over repeat injections or oral therapy, or Vivani has technology without a market.HoldingMateriality: High

    The company describes itself as a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting subdermal drug implant candidates. If the delivery advantage is real, Vivani can create platform value; if convenience, safety, or efficacy is not clearly superior, commercialization and partnering power collapse.

    Watch: Improved injectable or oral chronic-disease therapies reduce the adherence and convenience problem NanoPortal is meant to solve.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The company describes itself as a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting subdermal drug implant candidates.

    Open source ↗
  • Vivani must convert development work into clinical, regulatory, or partnering milestones before the cash runway erodes, because it has no operating cash inflow to self-fund the platform.WeakeningMateriality: High

    Cash was $16.232 million at FY2025 year-end. A successful milestone can finance the next stage on better terms; delays can force dilution or program cuts before the asset is de-risked.

    Watch: A trial delay, FDA clinical hold, or additional preclinical requirement pushes milestones beyond available funding.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $16.232 million at FY2025 year-end.

    Open source ↗
  • Because Vivani has no commercial revenue, the business model needs outside validation—clinical data, regulatory progress, or a development partner—before it can claim pricing power or durable enterprise value.WeakeningMateriality: Medium

    GAAP annual revenue was $0 in FY2025. External validation can change the company from a cash-consuming R&D project into a financeable platform; absence of validation leaves shareholders exposed to burn and dilution.

    Watch: Potential pharmaceutical partners choose internal long-acting formulations or established delivery technologies instead of NanoPortal.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue was $0 in FY2025.

    Open source ↗
  • A small clinical-stage organization must keep spending tightly aimed at the Biopharm platform’s highest-value milestones rather than dispersing capital across too many programs or infrastructure needs.HoldingMateriality: Medium

    The company reported 36 employees as of March 26, 2026. Focused execution extends the odds of reaching value-inflecting data; unfocused spending shortens runway without proportionate de-risking.

    Watch: Headcount or spending expands materially before clear clinical validation.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The company reported 36 employees as of March 26, 2026.

    Open source ↗
  • Current holders need future financing to be non-dilutive, partnered, or raised after value-creating milestones; repeated low-quality equity issuance would shift much of NanoPortal’s upside away from existing shareholders.WeakeningMateriality: Medium

    Stockholders’ equity declined from $44.308 million at FY2022 year-end to $15.730 million at FY2025 year-end. Even if the platform works scientifically, per-share returns can disappoint if the company must sell too much equity before the value inflection.

    Watch: An at-the-market program, PIPE, warrant-heavy financing, or reverse-split-linked issuance occurs before meaningful clinical validation.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Stockholders’ equity declined from $44.308 million at FY2022 year-end to $15.730 million at FY2025 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

NanoPortal must create a real patient and prescriber advantage—reversible, ultra-long-acting, near constant-rate delivery—over repeat injections or oral therapy, or Vivani has technology without a market. If the delivery advantage is real, Vivani can create platform value; if convenience, safety, or efficacy is not clearly superior, commercialization and partnering power collapse.

Vivani must convert development work into clinical, regulatory, or partnering milestones before the cash runway erodes, because it has no operating cash inflow to self-fund the platform. A successful milestone can finance the next stage on better terms; delays can force dilution or program cuts before the asset is de-risked.

Because Vivani has no commercial revenue, the business model needs outside validation—clinical data, regulatory progress, or a development partner—before it can claim pricing power or durable enterprise value. External validation can change the company from a cash-consuming R&D project into a financeable platform; absence of validation leaves shareholders exposed to burn and dilution.

A small clinical-stage organization must keep spending tightly aimed at the Biopharm platform’s highest-value milestones rather than dispersing capital across too many programs or infrastructure needs. Focused execution extends the odds of reaching value-inflecting data; unfocused spending shortens runway without proportionate de-risking.

Current holders need future financing to be non-dilutive, partnered, or raised after value-creating milestones; repeated low-quality equity issuance would shift much of NanoPortal’s upside away from existing shareholders. Even if the platform works scientifically, per-share returns can disappoint if the company must sell too much equity before the value inflection.

All standing thesis claims
Original report summary

Vivani is a binary platform bet: NanoPortal implants must prove they can make chronic-drug delivery easier and more consistent before cash burn and dilution overwhelm the option value.

Evidence assessed Nov 21, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Vivani Medical

Where the evidence on Vivani Medical disagrees: Mixed on the latest evidence (Nov 21, 2026). Of its 5 thesis points, 2 holding and 3 weakening.

Bull case: what the evidence supports

  • NanoPortal must create a real patient and prescriber advantage—reversible, ultra-long-acting, near constant-rate delivery—over repeat injections or oral therapy, or Vivani has technology without a market.

    sec.gov ↗

  • A small clinical-stage organization must keep spending tightly aimed at the Biopharm platform’s highest-value milestones rather than dispersing capital across too many programs or infrastructure needs.

    sec.gov ↗

Bear case: what the evidence questions

  • Vivani must convert development work into clinical, regulatory, or partnering milestones before the cash runway erodes, because it has no operating cash inflow to self-fund the platform.

    sec.gov ↗

  • Because Vivani has no commercial revenue, the business model needs outside validation—clinical data, regulatory progress, or a development partner—before it can claim pricing power or durable enterprise value.

    sec.gov ↗

  • Current holders need future financing to be non-dilutive, partnered, or raised after value-creating milestones; repeated low-quality equity issuance would shift much of NanoPortal’s upside away from existing shareholders.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Vivani Medical

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Vivani Medical’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Entered a material definitive agreement.

    Vivani Medical filed an SEC 8-K on 2026-11-16: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    Vivani Medical filed an SEC 8-K on 2026-11-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Regulation FD disclosure.

    Vivani Medical filed an SEC 8-K on 2026-10-30: Regulation FD disclosure. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Improved injectable or oral chronic-disease therapies reduce the adherence and convenience problem NanoPortal is meant to solve.
  • A trial delay, FDA clinical hold, or additional preclinical requirement pushes milestones beyond available funding.
  • Potential pharmaceutical partners choose internal long-acting formulations or established delivery technologies instead of NanoPortal.
  • Headcount or spending expands materially before clear clinical validation.
  • An at-the-market program, PIPE, warrant-heavy financing, or reverse-split-linked issuance occurs before meaningful clinical validation.

VANI news

Loading headlines…

Financial statements

VANI income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

VANI: quick answers

When does Vivani Medical (VANI) report earnings next?
Vivani Medical's next results are projected for February 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 12, 2026. Earnings calendar
What is VANI's short interest?
As of October 30, 2026, 369,789 VANI shares were sold short, 0.41% of its shares outstanding, down 11.4% from the count before. At the stock's average daily volume that is 2.0 days to cover. FINRA publishes the count twice a month. VANI short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.